WO2004035083A3 - Compositions for the treatment of autoimmune disorders - Google Patents

Compositions for the treatment of autoimmune disorders Download PDF

Info

Publication number
WO2004035083A3
WO2004035083A3 PCT/GB2003/004537 GB0304537W WO2004035083A3 WO 2004035083 A3 WO2004035083 A3 WO 2004035083A3 GB 0304537 W GB0304537 W GB 0304537W WO 2004035083 A3 WO2004035083 A3 WO 2004035083A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
autoimmune disorders
raises
antigen
Prior art date
Application number
PCT/GB2003/004537
Other languages
French (fr)
Other versions
WO2004035083A2 (en
Inventor
Rodney William Kelly
Original Assignee
Medical Res Council
Rodney William Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Rodney William Kelly filed Critical Medical Res Council
Priority to EP03758329A priority Critical patent/EP1556075A2/en
Priority to AU2003274342A priority patent/AU2003274342A1/en
Priority to JP2004544500A priority patent/JP2006508936A/en
Priority to US10/532,291 priority patent/US20060233743A1/en
Publication of WO2004035083A2 publication Critical patent/WO2004035083A2/en
Publication of WO2004035083A3 publication Critical patent/WO2004035083A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient an agent which raises the effective cAMP concentration in a monocyte cell and GMCSF or a derivative thereof. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is a prostaglandin or agonist thereof which stimulates cAMP production in a monocyte. Optionally, the antigen to which it is desired to induce tolerance, or a derivative thereof, may also be administered.
PCT/GB2003/004537 2002-10-21 2003-10-21 Compositions for the treatment of autoimmune disorders WO2004035083A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03758329A EP1556075A2 (en) 2002-10-21 2003-10-21 Compositions for the treatment of autoimmune disorders
AU2003274342A AU2003274342A1 (en) 2002-10-21 2003-10-21 Compositions for the treatment of autoimmune disorders
JP2004544500A JP2006508936A (en) 2002-10-21 2003-10-21 Therapeutic compositions and methods
US10/532,291 US20060233743A1 (en) 2002-10-21 2003-10-21 Compositions and methods of therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0224415.0A GB0224415D0 (en) 2002-10-21 2002-10-21 Compositions
GB0224415.0 2002-10-21

Publications (2)

Publication Number Publication Date
WO2004035083A2 WO2004035083A2 (en) 2004-04-29
WO2004035083A3 true WO2004035083A3 (en) 2004-11-18

Family

ID=9946261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004537 WO2004035083A2 (en) 2002-10-21 2003-10-21 Compositions for the treatment of autoimmune disorders

Country Status (6)

Country Link
US (1) US20060233743A1 (en)
EP (1) EP1556075A2 (en)
JP (1) JP2006508936A (en)
AU (1) AU2003274342A1 (en)
GB (1) GB0224415D0 (en)
WO (1) WO2004035083A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104022A2 (en) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
WO2005029091A2 (en) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
GB0324523D0 (en) * 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
WO2012142492A2 (en) * 2011-04-15 2012-10-18 University Of Georgia Research Foundation, Inc. Methods for inhibiting virus replication
WO2013049846A1 (en) * 2011-09-30 2013-04-04 Pawel Kalinski Generation of immunosuppressive myeloid cells using pge2
PL2782584T3 (en) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2877199A1 (en) * 2012-07-20 2015-06-03 Trifoilium ApS Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015110536A1 (en) * 2014-01-22 2015-07-30 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy
US10105415B2 (en) 2014-07-24 2018-10-23 Reponex Pharmaceuticals A/S Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
US10369219B2 (en) 2014-08-04 2019-08-06 Nitto Denko Corporation Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3125226C (en) * 2018-12-29 2023-10-10 Shanghai Archeus Biotech Co., Ltd. Immunosuppressive pharmaceutical composition and use thereof
KR20220093208A (en) * 2019-11-07 2022-07-05 라이프엑스 바이오랩스, 인코포레이티드 Prostaglandin analogs and their uses
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012563A2 (en) * 1997-09-11 1999-03-18 The Governemnt Of The United States Of America, Represented By The Department Of Health And Human Services Mucosal cytotoxic t lymphocyte responses
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
WO2000064260A1 (en) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
US6458585B1 (en) * 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4127612A (en) * 1978-03-17 1978-11-28 Miles Laboratories, Inc. 19-Hydroxy PGE1 carbinol analogues
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
GB9406463D0 (en) * 1994-03-31 1994-05-25 Medical Res Council Cervical ripening
AU4270596A (en) * 1994-12-23 1996-07-19 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
US6280718B1 (en) * 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US6458585B1 (en) * 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO1999012563A2 (en) * 1997-09-11 1999-03-18 The Governemnt Of The United States Of America, Represented By The Department Of Health And Human Services Mucosal cytotoxic t lymphocyte responses
WO2000064260A1 (en) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ICHIMURA HIROSHI ET AL: "Differentiation of a cell line of human cervical argyrophil small cell carcinoma to macrophage lineage cells", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 90, no. 5, May 1999 (1999-05-01), pages 523 - 529, XP002294672, ISSN: 0910-5050 *
KALINSKI P ET AL: "Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1997, vol. 417, 1997, pages 363 - 367, XP009027784, ISSN: 0065-2598 *
PIQUET-PELLORCE C ET AL: "PROSTAGLANDIN E-2 POTENTIATES GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR-INDUCED HISTAMINE SYNTHESIS IN BONE MARROW CELLS ROLE OF CYCLIC AMP", LIFE SCIENCES, vol. 48, no. 25, 1991, &, pages 2377 - 2382, XP001180093, ISSN: 0024-3205 *
STEINBRINK KERSTIN ET AL: "Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins", ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 292, no. 9, September 2000 (2000-09-01), &, pages 437 - 445, XP001180090, ISSN: 0340-3696 *

Also Published As

Publication number Publication date
US20060233743A1 (en) 2006-10-19
WO2004035083A2 (en) 2004-04-29
JP2006508936A (en) 2006-03-16
AU2003274342A8 (en) 2004-05-04
GB0224415D0 (en) 2002-11-27
EP1556075A2 (en) 2005-07-27
AU2003274342A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004035083A3 (en) Compositions for the treatment of autoimmune disorders
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EA200201124A1 (en) APPLICATION OF THE COMPOSITION CONTAINING CELCOXYB FOR FAST PAIN RELAXATION
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2004019884A3 (en) Agents and methods for enhancing bone formation
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MX348062B (en) Proteoglycan degrading mutants for treatment of cns.
EP2371859A3 (en) Treatment of TNF alpha related disorders
EP2298811A3 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
WO2005107726A3 (en) Method for the treatment of back pain
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EP2281561A3 (en) Use of LCK inhibitors for treatment of immunologic diseases
WO2003057223A8 (en) Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
WO2005086970A3 (en) Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
WO2003094957A3 (en) Methods of therapy for inducing tolerance
IL175357A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004544500

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003758329

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003758329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006233743

Country of ref document: US

Ref document number: 10532291

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10532291

Country of ref document: US